海外市场的突破性拓展成为业绩增长的核心引擎。2025年全球生物医药BD交易总额达1356.55亿美元，涉及157起交易，中国首次超越美国成为全球BD交易 最活跃市场。龙头企业纷纷通过海外授权与市场扩张斩获增量，三生国健凭借与辉瑞达成的707项目合作，获得约28.90亿元首付款收入，预计2025年归母净 利润同比增长311.35%至29亿元。CXO龙头药明康德表现亮眼，预计2025年归母净利润191.51亿元，同比激增102.65%，其"一体化、端到端"CRDMO模式持 续吸引全球客户，海外订单复苏态势显著。通化东宝的国际化战略成效凸显，胰岛素制剂已在5个新兴市场国家获批，门冬胰岛素美国BLA获FDA受理，出 口收入成为业绩重要增长点。和众汇富观察发现，国产药企正从"快速跟进"向"全球新"输出转型，出海赛道逐渐成为板块估值提升的核心主线。 截至2026年1月26日，Wind数据显示已有逾90家A股生物医药公司披露2025年业绩预告，其中53家预计实现盈利，14家公司净利润增幅下限超100%，多家企 业实现扭亏为盈或大幅减亏。在行业景气度持续回暖、海外市场加速突破及政策红利密集释放的多重支撑下，A股生物医药板块正 ...

2025年，通化东宝国际化战略持续扩面提速，海外业务收入保持快速增长态势，成为公司业绩的重要增 长极。公司继2024年海外收入突破亿元大关、同比增长近80%后，2025年海外收入增长势头持续强劲， 海外拓展再获多项突破，产品出海版图持续扩大。 在产品国际注册方面，公司胰岛素制剂与GLP-1产品均取得积极进展。其中，胰岛素类似物方面，门冬 胰岛素美国BLA获得美国FDA受理，门冬胰岛素注射液在多米尼加、印尼获批上市，甘精胰岛素注射液 在缅甸获批上市；人胰岛素方面，精蛋白人胰岛素混合注射液(30R)在乌兹别克斯坦获批上市，精蛋白 人胰岛素注射液在尼加拉瓜获批上市；GLP-1产品方面，利拉鲁肽注射液获哥伦比亚GMP证书，利拉鲁 肽注射液接受埃及GMP现场审计，利拉鲁肽注射液通过巴西GMP现场审计，利拉鲁肽注射液在秘鲁获 批上市。 通化东宝持续强化创新研发，报告期内多个研发项目取得重要临床进展。其中，2025年6月，司美格鲁 肽顺利完成III期临床试验所有受试者的末次给药访视，目前已完成数据库锁定，正按计划开展试验总结 工作。2025年4月，XO/URAT1双靶点抑制剂(THDBH151片)IIa期临床试验结果达到主 ...

证券代码：603087 证券简称：甘李药业 公告编号：2026-006 甘李药业股份有限公司 2025年年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 1. 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升50%以上的情形。 2. 甘李药业股份有限公司（以下简称"公司"）预计2025年年度实现归属于母公司所有者的净利润为 11.00亿元到12.00亿元，与上年同期（法定披露数据）相比，将增加4.85亿元到5.85亿元，同比增加 78.96%到95.23%。 3. 公司预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润为7.00亿元至8.00亿元， 与上年同期（法定披露数据）相比，将增加2.70亿元到3.70亿元，同比增加62.63%到85.86%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1. 经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润为11.00亿元到12.00亿元， 与上年同 ...

2025年度，公司预计归属于母公司所有者的净利润较去年同期实现大幅增长，主要受益于国内外收入增 长、股权转让收益。(1)在国内市场，公司在集采获得的市场覆盖优势上，不断深耕和拓宽市场，胰岛 素制剂产品的销量与销售额同步实现大幅增长。(2)在国际市场，公司积极推进国际化战略，在"一带一 路"沿线及新兴市场拓展成效显著，成功赢得了更多国际客户的信任和合作机会，在多个关键市场取得 了销售增长。(3)2025年度，公司与广东横琴甘瓴企业管理有限责任公司(以下简称"横琴甘瓴")达成一致 协议，公司将全资子公司甘甘医疗科技江苏有限公司(以下简称"甘甘江苏")合计70%的股权分两步转让 予横琴甘瓴。2025年度，公司已完成首步交易，成功转让甘甘江苏55%的股权，投资收益增加，使公司 净利润增加。 智通财经APP讯，甘李药业(603087.SH)发布2025年年度业绩预增公告，预计2025年年度实现归属于母 公司所有者的净利润为11.00亿元到12.00亿元，与上年同期(法定披露数据)相比，将增加4.85亿元到5.85 亿元，同比增加78.96%到95.23%。 ...

2025年度，公司预计归属于母公司所有者的净利润较去年同期实现大幅增长，主要受益于国内外收入增 长、股权转让收益。(1)在国内市场，公司在集采获得的市场覆盖优势上，不断深耕和拓宽市场，胰岛 素制剂产品的销量与销售额同步实现大幅增长。(2)在国际市场，公司积极推进国际化战略，在"一带一 路"沿线及新兴市场拓展成效显著，成功赢得了更多国际客户的信任和合作机会，在多个关键市场取得 了销售增长。(3)2025年度，公司与广东横琴甘瓴企业管理有限责任公司(以下简称"横琴甘瓴")达成一致 协议，公司将全资子公司甘甘医疗科技江苏有限公司(以下简称"甘甘江苏")合计70%的股权分两步转让 予横琴甘瓴。2025年度，公司已完成首步交易，成功转让甘甘江苏55%的股权，投资收益增加，使公司 净利润增加。 甘李药业（603087）(603087.SH)发布2025年年度业绩预增公告，预计2025年年度实现归属于母公司所 有者的净利润为11.00亿元到12.00亿元，与上年同期(法定披露数据)相比，将增加4.85亿元到5.85亿元， 同比增加78.96%到95.23%。 ...

每经AI快讯，1月21日，甘李药业（603087）(603087.SH)发布2025年度业绩预告，预计归属于上市公司 股东的净利润为11.00亿元到12.00亿元，与上年同期相比增加78.96%到95.23%。报告期内，公司国内外 收入增长，胰岛素制剂产品销量与销售额大幅上升，国际化战略推进取得成效，同时因转让甘甘江苏 55%股权获得投资收益，带动净利润增长。 ...

Group 1 - The core focus of the news is the signing of 22 key projects in Beijing Economic-Technological Development Area, with over 80% of these projects being future industry initiatives [1][2] - The development strategy during the "14th Five-Year Plan" period aims to establish a robust ecosystem that enhances economic quality, urban appearance, and public welfare [1] - Notable projects include Baichang Intelligent Automotive's plan to establish a vehicle manufacturing company targeting L4 autonomous driving vehicles, with projected revenues reaching billions by 2030 [1] Group 2 - The AI sector is emphasized, with over 30% of the signed projects focusing on artificial intelligence, including ZTE's development of a 6G satellite payload production line [2] - The ten benchmark projects initiated include a biopharmaceutical raw material base by Sanofi, which will create a complete insulin production chain locally [2] - The development plan includes significant investments in urban infrastructure and ecological governance, reflecting a shift towards comprehensive regional development [2] Group 3 - The development strategy prioritizes talent and human creativity, with plans for enhanced living conditions, entrepreneurial support, and educational facilities [3] - The "2026 Ten Plans for Optimizing the Business Environment" aims to create a conducive environment for new productive forces, focusing on foundational improvements and innovation [3] - The future vision for the economic zone includes accelerated technological innovation, improved living standards, and enhanced integration of industry and urban development [3]

Core Insights - Beijing Economic-Technological Development Area (BDA) aims to establish a high-quality business environment and enhance new productive forces during the 14th Five-Year Plan period, focusing on economic quality, urban appearance, and public welfare improvements [1] Group 1: Project Developments - 22 key projects were signed and initiated on the first working day of 2026, with over 80% of these projects focusing on future industries [2] - Notable projects include Baichang Intelligent Automotive's plan to establish a vehicle manufacturing company for L4 autonomous vehicles, targeting revenues of billions by 2030 [2] - ZTE Corporation is focusing on AI and 6G technologies, having established six companies in the BDA, with significant advancements in core technologies and production lines [2] Group 2: Infrastructure and Urban Development - The ten benchmark projects initiated include a biopharmaceutical raw material base by Sanofi, which will create a complete insulin production chain locally [3] - Investments in urban infrastructure and ecological governance have increased significantly, with projects like the expansion of Tongren Hospital and ecological improvements at Tongming Lake [3] Group 3: Business Environment Optimization - BDA has launched the "Top Ten Plans for Optimizing the Business Environment" to enhance the institutional framework for new productive forces [4] - The focus will be on reforming and innovating to eliminate barriers to productivity, thereby stimulating innovation and creativity across society [4] - The development blueprint indicates that BDA will strengthen its role as a driving force for economic development in the capital, with improvements in living standards and urban integration [4]

Core Viewpoint - Ganli Pharmaceutical announced the dismissal of its financial officer and vice president, Sun Cheng, due to the strategic need for global upgrades in innovative drug research and marketing, effective immediately upon board approval [1][6]. Group 1: Personnel Changes - Sun Cheng's departure means he will no longer hold any position within the company, with his original term set to expire on May 20, 2028 [1][6]. - The board has appointed Ms. Zhou Li to act as the financial officer following Sun Cheng's departure [5][10]. Group 2: Financial Performance - For the third quarter of 2025, Ganli Pharmaceutical reported a revenue of 3.05 billion yuan, representing a year-on-year increase of 35.7% [5][10]. - The net profit attributable to shareholders reached 818 million yuan, up 61.3% year-on-year, while the net profit excluding non-recurring items was 692 million yuan, reflecting a significant increase of 122.8% [5][10]. - The growth in revenue was driven by increased sales of domestic insulin preparations, and the company has strengthened its market share internationally through improved product quality and customer service [5][10].

Core Insights - The company reported significant growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 3.047 billion yuan and net profit at 818 million yuan, representing year-on-year increases of 35.73% and 61.32% respectively [1][2]. Group 1: Revenue Growth - Domestic sales revenue for the first three quarters of 2025 was 2.690 billion yuan, up 44.01%, while international sales revenue was 353 million yuan, up 45.52% [2]. - The growth in revenue is attributed to the price increase following the continuation of domestic insulin procurement and the expansion of international market sales [2][3]. Group 2: Domestic Sales Performance - Domestic insulin formulation revenue reached 2.624 billion yuan, reflecting a year-on-year growth of 45.6%, with volume contributing 27.3% and price contributing 18.3% to this growth [3]. Group 3: Global Strategy - The company is actively pursuing a global strategy, resulting in high growth in international sales, including a 10-year technical transfer and supply agreement with Brazil, with a total order value of no less than 3 billion yuan [4]. Group 4: R&D Pipeline - The company is advancing its insulin weekly formulation, which is expected to become a cornerstone drug for diabetes treatment globally, with several projects in clinical trials progressing well [5]. Group 5: Investment Outlook - The company forecasts net profits of 1.109 billion yuan, 1.432 billion yuan, and 1.595 billion yuan for 2025 to 2027, with respective year-on-year growth rates of 80.4%, 29.1%, and 11.4% [6].